Arrowhead Pharmaceuticals Reports Positive Phase 3 Results for Plozasiran

Arrowhead Pharmaceuticals has announced encouraging results from its Phase 3 trials for plozasiran, a treatment for severe hypertriglyceridemia. The drug not only met its primary endpoint of reducing triglyceride levels but also significantly decreased acute pancreatitis events, particularly in high-risk patients. This development could have a substantial impact on managing a condition that poses serious health risks.